Gameto, a clinical-stage biotech company focused on stem cell-derived therapies for reproductive health, announced on August 12, 2025, that it has secured $44 million in Series C funding, led by Overwater Ventures with contributions from a broad consortium of investors. This brings Gameto’s total funding to $127 million, underscoring confidence in its scientific progress and potential to reshape reproductive care.
The funding will propel the completion of the Phase 3 trial for Gameto’s lead candidate, Fertilo, as well as facilitate regulatory approval efforts worldwide. Fertilo, already commercial in countries such as Peru, Mexico, Australia, Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay, has achieved five births and over 20 pregnancies so far. Notably, it is the first iPSC-derived therapy to reach late-stage clinical development in the U.S.
Gameto’s FIRST trial (Fertilo In Vitro Research Study and Trial) is pioneering: it’s the first randomized, controlled, double-blind study in the U.S. to assess ex vivo egg maturation using engineered ovarian support cells derived from induced pluripotent stem cells. This method aims to dramatically reduce traditional IVF’s two-week hormone regimen to just 2–3 days. The trial is enrolling across up to 20 U.S. sites—including Shady Grove Fertility—and will later expand to institutions like Columbia University and Prelude Fertility. An interim readout is expected in late 2026, potentially paving the way for Fertilo’s market entry.
CEO Dr. Dina Radenkovic Turner emphasized that the funding will enable the firm to complete its pivotal trial and advance its broader mission in women’s and family health. Kristina Simmons from Overwater Ventures hailed Gameto’s innovative blend of breakthrough science and strategic vision, while co-founder Martin Varsavsky highlighted Fertilo’s capacity to transform IVF accessibility and safety.
Beyond Fertilo, Gameto is advancing AMENO, a menopause-focused therapeutic initiative supported by ARPA-H. This program aims to restore hormonal balance via an implantable therapy and to replicate natural hormone cycles with a vaginal ring, the latter of which is nearing Phase 1 trial readiness. These efforts are anchored in Gameto’s proprietary AI-based in vitro organoid platform developed in collaboration with George Church’s lab at Harvard, designed for disease modeling and drug discovery in female reproductive health.
Founded by Dr. Turner and Martin Varsavsky and evolving from Harvard’s research environment, Gameto has raised $127 million to date and is advancing therapies for fertility, menopause, and broader women’s health—currently with Fertilo in Phase 3.
